Concepedia

Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials

Arturo Cesaro, Daniele Pastori, Vincenzo Acerbo, Flavio Giuseppe Biccirè, Michele Golino, Domenico Panico, Francesco Prati, Antonio Abbate, Gregory Y.H. Lip, Paolo Calabrò

European Journal of Preventive Cardiology · 2025 · 16 citations · 37 references

DOIFull text

Open access

Abstract

Treatment with semaglutide significantly reduces the incidence of new-onset AF. This effect appears more evident with the oral formulation and independent of baseline characteristics.

References

37

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

David Moher, A. Liberati, Jennifer Tetzlaff et al. · BMJ · 2009 · 82.3K citations · Full text

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John Wilding, Rachel L. Batterham, Salvatore Calanna et al. · New England Journal of Medicine · 2021 · 3.9K citations

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun et al. · New England Journal of Medicine · 2023 · 2.1K citations · Full text

2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Isabelle C. Van Gelder, Michiel Rienstra, Karina V Bunting et al. · European Heart Journal · 2024 · 1.8K citations · Full text

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al. · New England Journal of Medicine · 2019 · 1.8K citations · Full text